Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer - Related Studies

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

This study is currently recruiting participants.

Study NCT00660101. Last updated on December 3, 2008. Information provided by AVAX Technologies

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Adenocarcinoma of the Ovary

2	Additional conditions recognized in this trial
		Adenocarcinoma
		Ovarian Neoplasms

3	More general conditions related to this trial
		Adnexal Diseases
		Carcinoma
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Ovarian Diseases
		Urogenital Neoplasms

4	Sponsors listed in this trial
		AVAX Technologies